Bevacizumab-induced laryngeal necrosis

Ann Oncol. 2012 Jan;23(1):276-278. doi: 10.1093/annonc/mdr515. Epub 2011 Nov 4.

Authors

D M Hartl¹, R Bahleda², A Hollebecque², J Bosq³, C Massard², J C Soria²

Affiliations

¹ Department of Head and Neck Oncology, Institut Gustave Roussy, Villejuif. Electronic address: dana.hartl@igr.fr.
² Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif.
³ Department of Pathology, Institut Gustave Roussy, Villejuif, France.

PMID: 22056850
DOI: 10.1093/annonc/mdr515

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Carboplatin / administration & dosage
Cisplatin / administration & dosage
Clinical Trials, Phase I as Topic
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Female
Gemcitabine
Glutamates / administration & dosage
Guanine / administration & dosage
Guanine / analogs & derivatives
Humans
Laryngeal Diseases / chemically induced*
Lung Neoplasms / drug therapy
Middle Aged
Necrosis / chemically induced
Neoplasm Recurrence, Local / drug therapy
Paclitaxel / administration & dosage
Pemetrexed
Tubulin Modulators / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Glutamates
Tubulin Modulators
Pemetrexed
Deoxycytidine
Bevacizumab
Guanine
Carboplatin
Paclitaxel
Cisplatin
Gemcitabine